Clinical Significance of Intramural Metastasis as an Independent Prognostic Factor in Esophageal Squamous Cell Carcinoma

被引:2
作者
Ushimaru, Yuki [1 ]
Makino, Tomoki [1 ]
Tanaka, Koji [1 ]
Yamashita, Kotaro [1 ]
Saito, Takuro [1 ]
Yamamoto, Kazuyoshi [1 ]
Takahashi, Tsuyoshi [1 ]
Kurokawa, Yukinori [1 ]
Nakajima, Kiyokazu [1 ]
Morii, Eiichi [2 ]
Eguchi, Hidetoshi [1 ]
Doki, Yuichiro [1 ]
机构
[1] Osaka Univ, Dept Gastroenterol Surg, Grad Sch Med, Osaka, Japan
[2] Osaka Univ, Dept Pathol, Grad Sch Med, Osaka, Japan
关键词
PREOPERATIVE CHEMOTHERAPY; LYMPHATIC DRAINAGE; 7TH EDITION; CANCER; FLUOROURACIL; SPREAD;
D O I
10.1245/s10434-023-13464-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Although intramural metastasis (IM) in esophageal cancer is considered a poor prognostic factor, there are only limited reports detailing its clinicopathologic characteristics and prognostic impact.Patients and Methods. We retrospectively included patients with esophageal squamous cell carcinoma (ESCC) with esophagectomy at our institution between 2010 and 2016. We compared patients with intramural metastases (IMs) (IM group) versus those without IMs (non-IM group) to clarify the clinical significance of intramural metastasis in ESCC.Results. A total of 23 (3.9%) out of all 597 patients were identified to have IM. The IMs were located on the cranial side in 13 (56.5%) and caudal side in 10 (43.5%) of the primary tumor, with two multiple cases. The IM group, compared with the non-IM group, was associated with higher percentage of cN-positive (91.3 versus 67.9%, P = 0.02), pN-positive (82.6 versus 55.9%, P = 0.04), and pM(lym)-positive (30.4 versus 12.5%, P = 0.02) cases. Five-year recurrence-free survival (RFS) was significantly worse in the IM group than the non-IM group (14.9 versus 55.0 %, P < 0.001). Multivariable analysis of recurrence-free survival identified pT (HR 1.74, 95% CI 1.36-2.23, P < 0.001), pN (HR 2.11, 95% CI 1.60-2.78, P < 0.001), histological classification (HR 1.68, 95% CI 1.21-2.35, P = 0.002), and pM(LYM) (HR 1.64, 95% CI 1.64-2.95, P < 0.001), along with presence of IM (HR 2.24, 95% CI 1.37-3.64, P < 0.001) to be independent prognostic factors. Lymphatic (65.2 versus 24.9%, P < 0.001) and hepatic (26.1 versus 6.8%, P = 0.005) recurrences were significantly more common in the IM group than in the non-IM group.Conclusions. IM was shown to be associated with dismal survival after surgery. A treatment strategy emphasizing more intensive systemic control should be considered for patients with ESCC with IM.
引用
收藏
页码:5195 / 5202
页数:8
相关论文
共 41 条
[1]   The significance of lymph node status as a prognostic factor for esophageal cancer [J].
Akutsu, Yasunori ;
Matsubara, Hisahiro .
SURGERY TODAY, 2011, 41 (09) :1190-1195
[2]   Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study - JCOG9204 [J].
Ando, N ;
Iizuka, T ;
Ide, H ;
Ishida, K ;
Shinoda, M ;
Nishimaki, T ;
Takiyama, W ;
Watanabe, H ;
Isono, K ;
Aoyama, N ;
Makuuchi, H ;
Tanaka, O ;
Yamana, H ;
Ikeuchi, S ;
Kabuto, T ;
Nagai, K ;
Shimoda, Y ;
Kinjo, Y .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4592-4596
[3]   A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) [J].
Ando, Nobutoshi ;
Kato, Hoichi ;
Igaki, Hiroyasu ;
Shinoda, Masayuki ;
Ozawa, Soji ;
Shimizu, Hideaki ;
Nakamura, Tsutomu ;
Yabusaki, Hiroshi ;
Aoyama, Norio ;
Kurita, Akira ;
Ikeda, Kenichiro ;
Kanda, Tatsuo ;
Tsujinaka, Toshimasa ;
Nakamura, Kenichi ;
Fukuda, Haruhiko .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (01) :68-74
[4]   New insights in the lymphatic spread of oesophageal cancer and its implications for the extent of surgical resection [J].
Cense, H. A. ;
van Eijck, C. H. J. ;
Tilanus, H. W. .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2006, 20 (05) :893-906
[5]   Pathological Regression of Lymph Nodes Better Predicts Long-term Survival in Esophageal Cancer Patients Undergoing Neoadjuvant Chemotherapy Followed by Surgery [J].
Hagi, Takaomi ;
Makino, Tomoki ;
Yamasaki, Makoto ;
Yamashita, Kotaro ;
Tanaka, Koji ;
Saito, Takuro ;
Takahashi, Tsuyoshi ;
Kurokawa, Yukinori ;
Motoori, Masaaki ;
Kimura, Yutaka ;
Nakajima, Kiyokazu ;
Morii, Eiichi ;
Eguchi, Hidetoshi ;
Doki, Yuichiro .
ANNALS OF SURGERY, 2022, 275 (06) :1121-1129
[6]   Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma [J].
Hara, Hiroki ;
Tahara, Makoto ;
Daiko, Hiroyuki ;
Kato, Ken ;
Igaki, Hiroyasu ;
Kadowaki, Shigenori ;
Tanaka, Yoichi ;
Hamamoto, Yasuo ;
Matsushita, Hisayuki ;
Nagase, Michitaka ;
Hosoya, Yoshinori .
CANCER SCIENCE, 2013, 104 (11) :1455-1460
[7]   The Pattern of Residual Tumor After Neoadjuvant Chemotherapy for Locally Advanced Esophageal Cancer and Its Clinical Significance [J].
Hashimoto, Tadayoshi ;
Makino, Tomoki ;
Yamasaki, Makoto ;
Tanaka, Koji ;
Miyazaki, Yasuhiro ;
Takahashi, Tsuyoshi ;
Kurokawa, Yukinori ;
Motoori, Masaaki ;
Kimura, Yutaka ;
Nakajima, Kiyokazu ;
Morii, Eiichi ;
Mori, Masaki ;
Doki, Yuichiro .
ANNALS OF SURGERY, 2020, 271 (05) :875-884
[8]  
Hokamura N, 2000, J SURG ONCOL, V75, P117, DOI 10.1002/1096-9098(200010)75:2<117::AID-JSO8>3.0.CO
[9]  
2-U
[10]   Esophageal cancer: The mode of lymphatic tumor cell spread and its prognostic significance [J].
Hosch, SB ;
Stoecklein, NH ;
Pichlmeier, U ;
Rehders, A ;
Scheunemann, P ;
Niendorf, P ;
Knoefel, WT ;
Izbicki, JR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (07) :1970-1975